一项2b期临床试验显示，赛诺菲和Teva的duvakitug为溃疡性结肠炎和克罗恩病患者提供了持久的缓解。 A phase 2b trial shows duvakitug, from Sanofi and Teva, offers lasting relief for ulcerative colitis and Crohn’s disease patients.

萨诺菲和Teva开发的药物duvakitug的2b期试验显示,在治疗性结肠炎和克罗恩病方面,长期有希望的结果,随着时间的推移,症状持续改善和疾病活性降低. A phase 2b trial of duvakitug, a drug developed by Sanofi and Teva, showed promising long-term results in treating ulcerative colitis and Crohn’s disease, with sustained symptom improvement and reduced disease activity over time. 数据表明,治疗可能为患有这些慢性炎症的肠胃病人提供持久的好处。 The data suggest the treatment may offer durable benefits for patients with these chronic inflammatory bowel conditions.